Greenwich Lifesciences Inc (GLSI)
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead candidate, GP2, is being studied in a Phase III trial aimed at helping prevent breast cancer recurrence in patients who have already had surgery. The company is also advancing FLAMINGO-01, a Phase III study evaluating GLSI-100, which combines GP2 and GM-CSF, in HER2-positive breast cancer patients. Founded in 2006 and headquartered in Stafford, Texas, Greenwich LifeSciences changed its name from Norwell, Inc. in 2018. Its common stock trades on NASDAQ under the symbol GLSI.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GLSI
|
$19.47
|
40.6% Upside
|
Undervalued
|
$47.50
|
243.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-9.2x
|
38.7x
|
—
|
206.5 M
|
193.5 M
|
0.0%
|
50.3%
|
4.9
|
—
|
57.4%
|
